Skip to content
Longboard Pharmaceuticals Logo
  • About
    • Overview
    • Management
    • Board of Directors
  • Our Approach
    • Overview
    • GPCR Therapies
    • Pipeline
    • Publications
  • Patients
    • Our Commitment
    • Advocacy & Research Partners
    • Expanded Access Policy
  • Investors
    • News & Events
      • Events & Presentations
      • Press Releases
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
    • SEC Filings
    • Analyst Coverage
    • Governance
      • Overview
      • Committee Composition
    • IR Resources
      • Investor FAQs
      • Contact IR
      • Email Alerts
  • Longboard Life
    • Overview
    • Culture and Benefits
  • Contact
  • About
    • Overview
    • Management
    • Board of Directors
  • Our Approach
    • Overview
    • GPCR Therapies
    • Pipeline
    • Publications
  • Patients
    • Our Commitment
    • Advocacy & Research Partners
    • Expanded Access Policy
  • Investors
    • News & Events
      • Events & Presentations
      • Press Releases
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
    • SEC Filings
    • Analyst Coverage
    • Governance
      • Overview
      • Committee Composition
    • IR Resources
      • Investor FAQs
      • Contact IR
      • Email Alerts
  • Longboard Life
    • Overview
    • Culture and Benefits
  • Contact
  • About
    • Overview
    • Management
    • Board of Directors
  • Our Approach
    • Overview
    • GPCR Therapies
    • Pipeline
    • Publications
  • Patients
    • Our Commitment
    • Advocacy & Research Partners
    • Expanded Access Policy
  • Investors
    • News & Events
      • Events & Presentations
      • Press Releases
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
    • SEC Filings
    • Analyst Coverage
    • Governance
      • Overview
      • Committee Composition
    • IR Resources
      • Investor FAQs
      • Contact IR
      • Email Alerts
  • Longboard Life
    • Overview
    • Culture and Benefits
  • Contact

Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers

Home » Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers

Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers

Juniper Point2023-12-01T00:56:24+00:0011.29.2023|
  • About
  • Our Approach
  • Patients
  • Investors
  • Longboard Life
  • Contact
[email protected]
(858) 789-9283
4275 Executive Square
Suite 950
La Jolla, CA 92037
Privacy Policy Terms of Use
XLinkedIn
Page load link
Go to Top